E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the maximal tolerated dose (MTD) of E2007
given twice daily (bid) or once a day (qd) in patients with refractory partial-onset seizures
(including secondarily generalized seizures). The secondary objectives are to evaluate the
safety, efficacy, concentration-efficacy relationship, and pharmacokinetics of E2007 and the
effects of E2007 on the Profile of Mood States (POMS) test.